Article Text

Download PDFPDF
Yin Yang 1 and farnesoid X receptor: a balancing act in non-alcoholic fatty liver disease?
  1. Vanessa Legry1,
  2. Frank G Schaap2,
  3. Bénédicte Delire1,
  4. Yves Horsmans1,
  5. Isabelle A Leclercq1
  1. 1Laboratory of Hepato-Gastroenterology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium
  2. 2Department of Surgery, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University, Maastricht, The Netherlands
  1. Correspondence to Professor Isabelle A Leclercq, Laboratoire d'Hépato-Gastro-Entérologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Avenue E Mounier 53, Box B1.52.01, Brussels 1200, Belgium; isabelle.leclercq{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. It comprises a spectrum ranging from bland steatosis or NAFL to non-alcoholic steatohepatitis (NASH) with or without fibrosis. There is a general consensus that patients with NAFLD have a very slow disease progression (if any). By contrast, patients with NASH can exhibit histological progression and can develop fibrosis, cirrhosis and hepatocellular carcinoma. Parenchymal inflammation is an important determinant of the severity and progression of the disease.

Increased fatty acid flux to the liver, from dietary absorption and from the adipose tissue, owing to insulin resistance, is a main contributor to increased hepatic lipid content. In addition, increased de novo lipogenesis, impaired mitochondrial fatty acid oxidation or decreased export of very low density lipoprotein triglyceride all play a part. Ligand-activated nuclear receptors control several key steps in lipid metabolism as well as inflammation and fibrogenesis and thus are potentially crucial players in NAFLD/NASH pathogenesis.1 One of those nuclear receptors is the bile salt sensor farnesoid X receptor (FXR). Besides regulating cholesterol and bile salt homeostasis, FXR is a key regulator of hepatic lipid metabolism. FXR, via induction of a short heterodimer partner, represses de novo lipogenesis. It induces peroxisome proliferator activated receptor (PPAR)α, and thus stimulates fatty acid β oxidation. The role of FXR is emphasised by the development of hepatosteatosis and hyperlipidaemia in FXR−/− mice.2 ,3 …

View Full Text


  • Contributors VL and IAL wrote the manuscript. FGS (as fibroblast growth factor 19/farnesoid X receptor specialist), BD and YH (as an expert in pharmacology) critically and constructively revised the manuscript for important intellectual content.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles